French validation of the Brief International Cognitive Assessment for Multiple Sclerosis.


Journal

Revue neurologique
ISSN: 0035-3787
Titre abrégé: Rev Neurol (Paris)
Pays: France
ID NLM: 2984779R

Informations de publication

Date de publication:
Historique:
received: 24 01 2020
revised: 23 04 2020
accepted: 24 04 2020
pubmed: 28 7 2020
medline: 7 8 2021
entrez: 28 7 2020
Statut: ppublish

Résumé

Cognitive impairment is important to consider in the assessment of multiple sclerosis (MS) patients. A short battery of cognitive assessment, the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS), has been developed to address the need for rapid assessment by combining 3 tests assessing the main cognitive spheres reached in MS. To establish regression-based norms of the BICAMS in French speaking healthy subjects (HS) and validate its use in persons with multiple sclerosis (PwMS). In all, 123 PwMS including 40 with relapsing-remitting MS, 41 patients with secondary progressive MS and 42 with primary progressive MS and 276 HS were evaluated by the BICAMS including 3 tests, the Symbol Digit Modalities Test (SDMT), the French Verbal learning test (FVLT) a French-adapted memory test, (or the California Verbal Learning Test (CVLT) at retesting) and the Brief Visuo-Spatial Memory Test (BVMT-R). The standards for these tests were established in the healthy population using a multiple regression technique. Validity in MS was measured. Regression-based norms of BICAMS tests have been established in the HS population. 50.4% of PwMS have impairment for at least one BICAMS test (-1.5SD on the Z-score). The most common pathological test was the FVLT altered in 36.6% of patients, followed by the SDMT and the BVMT-R. The re-test reliability was good for the various BICAMS tests, 0.891 for SDMT, 0.781 for FVLT/CVLT and 0.669 for BVMT-R. This study establishes the validity of the BICAMS as a short and easy to apply battery for a brief assessment of the speed of information processing and episodic memory in MS.

Sections du résumé

BACKGROUND BACKGROUND
Cognitive impairment is important to consider in the assessment of multiple sclerosis (MS) patients. A short battery of cognitive assessment, the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS), has been developed to address the need for rapid assessment by combining 3 tests assessing the main cognitive spheres reached in MS.
OBJECTIVES OBJECTIVE
To establish regression-based norms of the BICAMS in French speaking healthy subjects (HS) and validate its use in persons with multiple sclerosis (PwMS).
METHODS METHODS
In all, 123 PwMS including 40 with relapsing-remitting MS, 41 patients with secondary progressive MS and 42 with primary progressive MS and 276 HS were evaluated by the BICAMS including 3 tests, the Symbol Digit Modalities Test (SDMT), the French Verbal learning test (FVLT) a French-adapted memory test, (or the California Verbal Learning Test (CVLT) at retesting) and the Brief Visuo-Spatial Memory Test (BVMT-R). The standards for these tests were established in the healthy population using a multiple regression technique. Validity in MS was measured.
RESULTS RESULTS
Regression-based norms of BICAMS tests have been established in the HS population. 50.4% of PwMS have impairment for at least one BICAMS test (-1.5SD on the Z-score). The most common pathological test was the FVLT altered in 36.6% of patients, followed by the SDMT and the BVMT-R. The re-test reliability was good for the various BICAMS tests, 0.891 for SDMT, 0.781 for FVLT/CVLT and 0.669 for BVMT-R.
CONCLUSION CONCLUSIONS
This study establishes the validity of the BICAMS as a short and easy to apply battery for a brief assessment of the speed of information processing and episodic memory in MS.

Identifiants

pubmed: 32713736
pii: S0035-3787(20)30610-X
doi: 10.1016/j.neurol.2020.04.028
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

73-79

Informations de copyright

Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Auteurs

N Maubeuge (N)

Université Poitiers, 86000 Poitiers, France; CHU de Bordeaux, 33000 Bordeaux, France.

M S A Deloire (MSA)

CHU de Bordeaux, 33000 Bordeaux, France.

B Brochet (B)

CHU de Bordeaux, 33000 Bordeaux, France; Inserm U1215 - Neurocentre Magendie, 33000 Bordeaux, France; Université Bordeaux, 33076 Bordeaux, France. Electronic address: bruno.brochet@chu-bordeaux.fr.

N Erhlé (N)

CHU de Reims, 51000 Reims, France.

J Charré-Morin (J)

CHU de Bordeaux, 33000 Bordeaux, France.

A Saubusse (A)

CHU de Bordeaux, 33000 Bordeaux, France.

A Ruet (A)

CHU de Bordeaux, 33000 Bordeaux, France; Inserm U1215 - Neurocentre Magendie, 33000 Bordeaux, France; Université Bordeaux, 33076 Bordeaux, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH